ArticleBMC cancer2021
The platelet to lymphocyte ratio is a potential inflammatory marker predicting the effects of adjuvant chemotherapy in patients with stage II colorectal cancer.
Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- The Prognostic Significance of Platelet-to-Lymphocyte Ratio and Lymphocyte-to-Monocyte in Colorectal Cancer: a Meta-Analysis.Journal of gastrointestinal cancer · 2025Pooled it
- Prognostic value of platelet to lymphocyte ratio in patients with colorectal cancer undergoing chemotherapy: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Prognostic role of systemic inflammation response index in patients with non-small cell lung cancer: a meta-analysis.BMJ open · 2024Pooled it
- Pooled it
- Prognostic role of systemic inflammation response index (SIRI) in patients with pancreatic cancer: a meta-analysis.Frontiers in oncology · 2024Pooled it
- Prognostic role of C-reactive protein in patients with endometrial cancer: a meta-analysis.Biomarkers in medicine · 2024Pooled it
- Prognostic value of pretreatment systemic immune-inflammation index in patients with endometrial cancer: a meta-analysis.Biomarkers in medicine · 2024Pooled it
- Platelet to lymphocyte ratio in the healthy population of Vojvodina.Journal of medical biochemistry · 2026Article
- The Evaluation of Diagnostic, Prognostic, and Predictive Role of Hematologic Inflammatory Indices NLR, PLR, and LMR in Common Solid Tumors.Cancer reports (Hoboken, N.J.) · 2025Review
- Prognostic value of inflammatory-nutritional indexes and HALP score in advanced stage NSCLC treated with first-line TKI.Biomarkers in medicine · 2025Article
- Clinical and histopathological evaluation of 5-fluorouracil-induced oral mucositis in a rat model.Open veterinary journal · 2025Article
- Liquid Biopsies in the Early Diagnosis, Prognosis, and Tailored Treatment of Colorectal Cancer.Cancers · 2025Review
- Clinical application of liquid biopsy in colorectal cancer: detection, prediction, and treatment monitoring.Molecular cancer · 2024Review
- Modified Naples prognostic score for evaluating the prognosis of patients with obstructive colorectal cancer.BMC cancer · 2023Article
- Prognostic role of preoperative inflammatory markers in postoperative patients with colorectal cancer.Frontiers in oncology · 2023Article
- Expression and Predictive Value of Serum NLR, PLR Combined with SAA in Patients with Different Stages of Colorectal Cancer.Frontiers in surgery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe effects of adjuvant chemotherapy in patients with stage II colorectal cancer (CRC) has been in controversy for a long time. Our study aimed to find an effective inflammatory marker to predict the effects of chemotherapy.
methodsSeven hundred eight stage II CRC patients in our institution were included. The subpopulation treatment effect pattern plot (STEPP) analysis was used to determine the optimal inflammatory marker and cut-off value. Propensity score matching (PSM) was performed to balance discrepancy between the chemotherapy and non-chemotherapy group. Survival analyses based on overall survival (OS) and cancer-specific survival (CSS) were performed with Kaplan-Meier methods with log-rank test and Cox proportional hazards regression. The restricted mean survival time (RMST) was used to measure treatment effect.
resultsThe platelet to lymphocyte ratio (PLR) was chosen as the optimal marker with a cut-off value of 130 according to STEPP. In OS analysis, PLR was significantly associated with the effects of chemotherapy (interaction p = 0.027). In the low-PLR subgroup, the chemotherapy patients did not have a longer OS than the non-chemotherapy patients (HR: 0.983, 95% CI: 0.528-1.829). In the high-PLR subgroup, the chemotherapy patients had a significantly longer OS than the non-chemotherapy patients (HR: 0.371, 95% CI: 0.212-0.649). After PSM, PLR was still associated with the effects of chemotherapy. In CSS analysis, PLR was not significantly associated with the effects of chemotherapy (interaction p = 0.116). In the low-PLR subgroup, the chemotherapy patients did not have a longer CSS than the non-chemotherapy patients (HR: 1.016, 95% CI: 0.494-2.087). In the high-PLR subgroup, the chemotherapy patients had a longer CSS than the non-chemotherapy patients (HR: 0.371, 95% CI: 0.212-0.649). After PSM, PLR was not associated with the effects of chemotherapy.
conclusionsPLR is an effective marker to predict the effects of chemotherapy in patients with stage II CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.